Emgality-maker Lilly courts payers with new migraine ER data

Sales of Eli Lilly’s migraine and cluster headache med Emgality have lagged behind competitors from Amgen and Novartis and Teva Pharmaceutical. And in its push to bring payers on board, Lilly is deploying a full-court press with some new patient data.